We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Aureus Pharma has announces the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term.

Under the agreement, Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division. The Aureus Pharma databases will give sanofi-aventis researchers access to information on major therapeutic targets. These include GPCR protein receptors, nuclear receptors, kinase inhibitors, ion channels, as well as information relative to drug safety including data on ADME (absorption, distribution, metabolism, and excretion).

The new agreement reinforces the relationship between Aureus Pharma and sanofi-aventis, which has been in existence for seven years already. It also secures additional revenues for Aureus over the next three years.

"Sanofi-aventis' decision to extend the partnership for an additional three year period, as well as to acquire new knowledge bases, confirms the fact that Aureus' products are meeting the needs of the world's leading pharmaceutical companies," said Dr Jason Theodosiou, CEO of Aureus Pharma.

Aureus Pharma's information solutions are working for many of the world's most successful biopharmaceutical companies and prestigious research institutions.